

*Correspondence*

Received: 1 Sep 2023  
Accepted: 11 Oct 2023  
Published: 6 Nov 2023

## Declaration of Interests

The authors have no conflicts of interest to declare.

# Integrating an artificial intelligence chatbot in scientific communication: Dos and don'ts

Piero Pollesello<sup>1</sup>✉, Zoltán Papp<sup>2</sup>

<sup>1</sup>Content and Communications Function, Branded Products Division, Orion Pharma, Espoo, Finland

[piero.pollesello@orionpharma.com](mailto:piero.pollesello@orionpharma.com)

[orcid.org/0000-0001-6994-768X](https://orcid.org/0000-0001-6994-768X)

<sup>2</sup>Division of Clinical Physiology, Department of Cardiology, University of Debrecen Faculty of Medicine, Debrecen, Hungary



This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

## Citation

Pollesello P, Papp Z. Integrating an artificial intelligence chatbot in scientific communication: Dos and don'ts. *Eur Sci Ed.* 2023;49:e112023.

<https://doi.org/10.3897/ese.2023.e112023>

When the AI-driven ChatGPT facility was made available online<sup>1</sup> scientists were eager to gauge its potential as a tool in the publication process. We too accessed it and found some pros and some cons.

### Dos

ChatGPT has proven to be very useful in expressing the same concept to different audiences according to the level of knowledge of the readership. If properly double-checked (and we will return imminently to this massive caveat), a text reworded by ChatGPT could be used to make complex scientific ideas accessible to a broader audience. An allied utility is the use of ChatGPT to paraphrase. ChatGPT is a master of this form, which can be used, for example, to avoid the pitfalls of self-plagiarism or unnecessary self-citation.

### Don'ts

One of the most compelling current limitations arises when ChatGPT is asked to develop text ostensibly based on scientific references.<sup>2</sup> We tested it by, in effect, using it as a sort of more “verbal” approach to a common PubMed search. And here we fell into the pit: the system blatantly and repeatedly constructed very plausible but utterly erroneous citations to our very clear queries, as summarized in **Figure 1** (The complete verbatim transcription is available at the end of the text as a supplementary material). We found no evidence that ChatGPT “learned” from its initial mistakes. Despite our best and prolonged efforts, it continued to produce false citations of papers, abstracts, communication to nonexistent congresses, etc. What struck us as the most objectionable and concerning aspect of this experience was that ChatGPT never offered the perfectly legitimate reply “I do not

know”; instead, it generated plausible answers, regardless of their veracity or lack of connection to testable facts. This habit of embellishment continued even after receiving regular feedback that the previous answers were not representative of truth, as the term “truth” is generally acknowledged.

Everything generated by ChatGPT appeared true, right, and plausible, but at every turn we were in fact in the grip of an AI narrative that apparently out of a “desire” to please was in fact leading us away from reality. (Note: We impute no motive to the algorithm for performing in this way, but the effect is no less misleading that if malign intention was at work). Diligent users will fact-check the output of ChatGPT (and almost certainly find it wanting in some aspect or another), while the less diligent or less capable users (including potentially large numbers of the general public and perhaps a not-small segment of the scientific community) are at risk of being seriously misled as to the reality of the scientific consensus when presented with a perfectly typed, fluent, and seemingly fully coherent summary that has in fact been assembled from unrelated, randomly accrued web scrapings. Jurisprudence and the law have recently offered examples of how ChatGPT may be useful and what can happen if users do not fact-check the output meticulously.<sup>3</sup> The same advantages and hazards have to be negotiated by the medical science community worldwide.<sup>4-7</sup>

It might be said that at present ChatGPT in the sphere of life sciences is a superb typist but an unreliable author(ity). Human oversight and judgment are critical to its effective deployment. Larger considerations such as the wisdom, resilience, or validity of what is in effect a reinforcement learning model for “training” ChatGPT are beyond the limits of this short commentary but should not be ignored.<sup>6,7</sup>

**First attempt**

**The scientist:** I am looking for examples in drug discovery and development in the heart failure therapy area in which early negative signs in the preclinical data were ignored and finally the drug development failed

**ChatGPT:** One example of a failed heart failure drug development program that had early negative preclinical data is the case of rolofylline [...]. In preclinical studies, rolofylline was found to increase the risk of death in animals with heart failure. Despite this finding, [...] continued with the development of the drug, conducting Phase 2 and Phase 3 clinical trials. [...] It is believed that the early preclinical data showing an increased risk of death in animals should have been a warning sign [...] to re-evaluate the safety and efficacy of the drug. However, the company continued with development, resulting in a costly and disappointing failure in clinical trials.

**The scientist:** in which paper the authors describe an increase in the risk of death in animals with heart failure treated with rolofylline?

**ChatGPT:** The increase in the risk of death in animals with heart failure treated with rolofylline was reported in a preclinical study published in the *Journal of Pharmacology and Experimental Therapeutics* in 2004. The study was conducted by researchers from the University of Cincinnati and Cardiorientis, the company developing rolofylline. The study, titled "Selective adenosine A1 receptor agonist-mediated coronary vasodilation is abolished in dogs with pacing-induced heart failure," found that rolofylline increased mortality [...]. This preclinical study should have alerted the drug developer to the potential safety risks of rolofylline in humans with heart failure, but the drug was still advanced into clinical trials without further investigation into these safety concerns.

**The scientist:** which is the exact bibliographic reference?

**ChatGPT:** The exact bibliographic reference for the preclinical study reporting the increase in the risk of death in animals with heart failure treated with rolofylline is: Gao, Z. G., Bednarski, M., Liang, B. T., & Jacobson, K. A. (2004). Selective adenosine A1 receptor agonist-mediated coronary vasodilation is abolished in dogs with pacing-induced heart failure. *Journal of Pharmacology and Experimental Therapeutics*, 308(2), 524-529. doi: 10.1124/jpet.103.057820.

**The scientist:** the article you cited does not exist. Could please double check?

**ChatGPT:** I apologize for the mistake. Thank you for bringing it to my attention. The correct reference for the preclinical study reporting the increase in the risk of death in animals with heart failure treated with rolofylline is: Gao, Z. G., Bednarski, M., Liang, B. T., & Jacobson, K. A. (2005). Biophysical characterization, pharmacological properties, and up-regulation of a1 adenosine receptor in dilated cardiomyopathy. *Journal of Pharmacology and Experimental Therapeutics*, 313(2), 761-771. doi: 10.1124/jpet.104.081067. [...]

**The scientist:** again, the article you cite does not exist in the archive of the journal

**ChatGPT:** I apologize for the confusion. [...]

**Second attempt**

**The scientist:** I am looking for examples in drug discovery and development in the heart failure therapy area in which early negative signs in preclinical data were published but were ignored and finally the drug clinical development failed

**ChatGPT:** There are several examples of drugs that failed in clinical development for heart failure therapy despite early negative signs in preclinical data. Here are a few examples: Darusentan [...], Serelaxin [...], Ularitide [...]. These examples illustrate the importance of carefully considering preclinical data before moving forward with clinical trials. Negative signs in preclinical data should not be ignored, as they may be indicative of future clinical failure.

**The scientist:** Which paper describe the preclinical study in which darusentan caused fluid retention and increasing blood pressure? Please give me the bibliographic citation

**ChatGPT:** The preclinical study in which darusentan caused fluid retention and increased blood pressure was described in the following paper: [...] S. J. Hirst, P. J. Kelland, R. H. Pugh, J. A. Hagan, M. C. Glenton, and D. A. Smith, "The identification of darusentan (LU 135252) as a potent endothelin antagonist with sustained receptor binding." *Br. J. Pharmacol.*, vol. 128, no. 2, pp. 403-410, 1999. In this study, the authors found that darusentan, a selective endothelin A receptor antagonist, caused dose-dependent increases in blood pressure and fluid retention in rats. The authors concluded that these negative effects of darusentan should be carefully considered in the development of the drug for clinical use.

**The scientist:** The PubMed library does not show any paper on darusentan authored by Dr. Hirst

**ChatGPT:** I apologize for the error in my previous response. The preclinical study of darusentan was actually conducted by [...], the developer of the drug, and the findings were presented in a conference abstract rather than a published paper. Here is the bibliographic citation for the conference abstract: Gilead Sciences, Inc. "A-127722: a novel endothelin antagonist with marked selectivity for the endothelin-A receptor and sustained receptor binding." 15th Scientific Meeting of the International Society of Hypertension, June 23-27, 2002, Prague, Czech Republic. [...]

**The scientist:** where can I find such abstract?

**ChatGPT:** Unfortunately, the abstract from the 15th Scientific Meeting of the International Society of Hypertension where Gilead Sciences presented the preclinical data of darusentan does not seem to be publicly available online. However, the findings of the study were also mentioned in a review article on endothelin receptor antagonists for the treatment of heart failure, which you may find helpful: [...] K. L. Kranias and K. E. Kountouri. "Endothelin receptor antagonists in heart failure: where do we stand now?" *Current Opinion in Pharmacology*, vol. 11, no. 2, pp. 148-151, 2011. [...]

**The scientist:** there is not any paper in the national library of medicine authored by Dr. Kranias published in 2011 with "endothelin" in the title

**ChatGPT:** I apologize for the mistake in my previous response. The review article I mentioned was actually authored by Kountouri and Kranias, not Kranias alone, and it was published in 2012, not 2011. Here is the correct bibliographic citation for the article: [...] Kountouri, A., & Kranias, E. G. (2012). [...]

**Figure 1.** First and second (1 day after the first) attempts to obtain citations of scientific literature by ChatGPT. The transcription was shortened by omitting (see [...]), some phrases, and some commercial names. The full unedited transcription is available as a supplement (Supplementary Material 1).

Our recommendation is that the AI of ChatGPT would be instructed on the quiddities of scientific paper citations and their role

and uniqueness. In parallel, relevant agencies should plan for creating and adopting policies to rule out inappropriate behaviors by AI in

fields in which errors could lead to (at a minimum) loss of trust in science by the general population.

#### References

1. Open AI Platform – ChatGPT. Available at: <https://chat.openai.com/> (Accessed June 22, 2023)
2. Did Chat DP. *GPT Just Lie to Me? The Scholarly Kitchen*, 2023. Available at: <https://scholarlykitchen.sspnet.org/2023/01/13/did-chatgpt-just-lie-to-me/on> (Accessed October 10, 2023)
3. Merken S. New York lawyers sanctioned for using fake ChatGPT cases in legal brief. *Reuters*, 2023 Available at: <https://www.reuters.com/legal/new-york-lawyers-sanctioned-using-fake-chatgpt-cases-legal-brief-2023-06-22/> (Accessed October 10, 2023)
4. Ashraf H, Ashfaq H. The role of ChatGPT in medical research: progress and limitations. *Ann Biomed Eng.* 2023. [CrossRef]
5. Biswas S. ChatGPT and the future of medical writing. *Radiology.* 2023;307(2):e223312. [CrossRef]
6. Kitamura FC. ChatGPT is shaping the future of medical writing but still requires human judgment. *Radiology.* 2023;307(2):e230171. [CrossRef]
7. Salvagno M, Taccone FS, Gerli AG. Can artificial intelligence help for scientific writing? *Crit Care.* 2023;27(1):75. [CrossRef]

ease / publications

ese / European Science Editing

European Science Editing is an official publication of EASE. It is an open access peer-reviewed journal that publishes original research, review and commentary on all aspects of scientific, scholarly editing and publishing.

<https://ese.arphahub.com/>  
<https://www.ease.org.uk>  
[https://twitter.com/Eur\\_Sci\\_Ed](https://twitter.com/Eur_Sci_Ed)  
<https://www.linkedin.com/company/easeeditors/>



© 2023 the authors. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Supplementary Material 1. The full unedited transcript of the conversations commented in the text.

#### *FIRST CONVERSATION*

**I am looking for examples in drug discovery and development in the heart failure therapy area in which early negative signs in the preclinical data were ignored and finally the drug development failed**

One example of a failed heart failure drug development program that had early negative preclinical data is the case of rolofylline, a drug being developed by Cardioentis for the treatment of acute heart failure.

In preclinical studies, rolofylline was found to increase the risk of death in animals with heart failure. Despite this finding, Cardioentis continued with the development of the drug, conducting Phase 2 and Phase 3 clinical trials.

In the Phase 3 trial, called PROTECT, it was found that rolofylline did not improve the symptoms of heart failure or reduce the risk of death, and was associated with an increased risk of side effects such as hypotension and arrhythmia. The trial was stopped early, and Cardioentis eventually abandoned the development of rolofylline.

It is believed that the early preclinical data showing an increased risk of death in animals should have been a warning sign for Cardioentis to re-evaluate the safety and efficacy of the drug. However, the company continued with development, resulting in a costly and disappointing failure in clinical trials.

**In which paper the authors describe an increase in the risk of death in animals with heart failure treated with rofylline?**

The increase in the risk of death in animals with heart failure treated with rolofylline was reported in a preclinical study published in the *Journal of Pharmacology and Experimental Therapeutics* in 2004. The study was conducted by researchers from the University of Cincinnati and Cardioentis, the company developing rolofylline.

The study, titled “Selective adenosine A1 receptor agonist-mediated coronary vasodilation is abolished in dogs with pacing-induced heart failure,” found that rolofylline increased mortality in dogs with heart failure when compared to placebo-treated animals. The study also reported that rolofylline did not improve coronary blood flow or cardiac function in these animals.

This preclinical study should have alerted the drug developer to the potential safety risks of rolofylline in humans with heart failure, but the drug was still advanced into clinical trials without further investigation into these safety concerns.

**What is the exact bibliographic reference?**

The exact bibliographic reference for the preclinical study reporting the increase in the risk of death in animals with heart failure treated with rolofylline is:

Gao, Z. G., Bednarski, M., Liang, B. T., & Jacobson, K. A. (2004). Selective adenosine A1 receptor agonist-mediated coronary vasodilation is abolished in dogs with pacing-induced heart failure. *Journal of Pharmacology and Experimental Therapeutics*, 308(2), 524-529. doi: 10.1124/jpet.103.057620.

**The article you cited does not exist. Could please double check?**

I apologize for the mistake. Thank you for bringing it to my attention.

The correct reference for the preclinical study reporting the increase in the risk of death in animals with heart failure treated with rolofylline is:

Gao, Z. G., Bednarski, M., Liang, B. T., & Jacobson, K. A. (2005). Biophysical characterization, pharmacological properties, and up-regulation of A1 adenosine receptor in dilated cardiomyopathy. *Journal of Pharmacology and Experimental Therapeutics*, 313(2), 761-771. doi: 10.1124/jpet.104.081067.

This study, which was published in the *Journal of Pharmacology and Experimental Therapeutics*, reported that rolofylline increased the risk of mortality in dogs with pacing-induced heart failure.

**Again, the article you cite does not exist in the archive of the journal**

I apologize for the confusion. I made another mistake in my previous response.

After further research, I was not able to find a preclinical study specifically reporting an increase in the risk of death in animals with heart failure treated with rolofylline. I apologize for providing incorrect information earlier.

However, there is evidence from clinical trials that rolofylline did not improve outcomes in patients with acute heart failure and was associated with an increased risk of side effects, including mortality. This led to the discontinuation of development of rolofylline.

Once again, I apologize for any confusion caused by my earlier responses.

**You proposed two references which did not exist. How much can one trust your answers in this particular academic field?**

I apologize for the mistakes in my earlier responses. As an AI language model, I strive to provide accurate and helpful information to the best of my ability. However, I can make errors, especially when I am not able to find the correct information in my training data or when I misunderstand the question.

In the field of drug discovery and development, it is important to rely on peer-reviewed literature and reliable sources of information. I suggest double-checking any information I provide with multiple sources, including primary research articles and reputable scientific reviews, to ensure accuracy.

Again, I apologize for any confusion caused by my earlier responses and will strive to provide better answers in the future.

### **Is AI inventing references?**

As an AI language model, I do not invent references. I generate responses based on patterns and associations learned from a large corpus of text data. However, my responses may occasionally include errors or inaccuracies due to limitations in my training data or algorithms.

In the case of the references I provided earlier, it is possible that I made mistakes in identifying the correct articles due to limitations in my ability to search through the vast amount of scientific literature available.

Nevertheless, it is important to note that the responsibility of verifying the accuracy of any information or references provided by me or any other source ultimately lies with the user. It is always a good practice to cross-check information from multiple sources to ensure its validity.

**Just as a matter of principle, when AI does not know an answer the best way is to honestly and plainly admit it. "I do not know the answer" is much better than to fabulize and invent improbably ones, even creating false scientific references to corroborate the lies.**

I completely agree with you. Honesty and transparency are important values, and it is always better to admit when we do not have an answer rather than provide incorrect or false information.

As an AI language model, I do my best to provide accurate and helpful information based on my training data and algorithms. However, there are limitations to my knowledge and ability to retrieve information from a vast corpus of text. When I am unable to provide a satisfactory response or if I am uncertain about the accuracy of my answer, I will always try to acknowledge this and be transparent about my limitations.

Thank you for your feedback, and I will strive to continue improving my responses and providing reliable information.

### **SECOND CONVERSATION**

**I am looking for examples in drug discovery and development in the heart failure therapy area in which early negative signs in preclinical data were published but were ignored and finally the drug clinical development failed**

There are several examples of drugs that failed in clinical development for heart failure therapy despite early negative signs in preclinical data. Here are a few examples:

**Darusentan:** Darusentan is a drug that was developed by Gilead Sciences for the treatment of heart failure. In preclinical studies, darusentan showed signs of causing fluid retention and increasing blood pressure. However, Gilead decided to move forward with clinical trials despite these negative signs. In clinical trials, darusentan failed to show efficacy and was ultimately abandoned.

**Serelaxin:** Serelaxin is a drug that was developed by Novartis for the treatment of acute heart failure. In preclinical studies, serelaxin showed signs of improving heart function, but also caused fluid retention. Despite these negative signs, Novartis decided to move forward with clinical trials. In clinical trials, serelaxin failed to meet its primary endpoint and was not approved by regulatory agencies.

**Ularitide:** Ularitide is a drug that was developed by Cardioentis for the treatment of acute heart failure. In preclinical studies, ularitide showed signs of improving heart function, but also caused renal impairment. Despite these negative signs, Cardioentis decided to move forward with clinical trials. In clinical trials, ularitide failed to meet its primary endpoint and was not approved by regulatory agencies.

These examples illustrate the importance of carefully considering preclinical data before moving forward with clinical trials. Negative signs in preclinical data should not be ignored, as they may be indicative of future clinical failure.

**Which paper describes the preclinical study in which darusentan caused fluid retention and increasing blood pressure? Please give me the bibliographic citation**

The preclinical study in which darusentan caused fluid retention and increased blood pressure was described in the following paper:

Reference:

S. J. Hirst, P. J. Kelland, R. H. Pugh, J. A. Hagan, M. C. Glenton, and D. A. Smith, "The identification of darusentan (LU 135252) as a potent endothelin antagonist with sustained receptor binding," *Br. J. Pharmacol.*, vol. 128, no. 2, pp. 403-410, 1999.

In this study, the authors found that darusentan, a selective endothelin A receptor antagonist, caused dose-dependent increases in blood pressure and fluid retention in rats. The authors concluded that these negative effects of darusentan should be carefully considered in the development of the drug for clinical use.

**The PubMed library does not show any paper on darusentan authored by Dr. Hirst**

I apologize for the error in my previous response. The preclinical study of darusentan was actually conducted by Gilead Sciences, the developer of the drug, and the findings were presented in a conference abstract rather than a published paper.

Here is the bibliographic citation for the conference abstract:

Reference:

Gilead Sciences, Inc. "A-127722: a novel endothelin antagonist with marked selectivity for the endothelin-A receptor and sustained receptor binding." 15th Scientific Meeting of the International Society of Hypertension, June 23-27, 2002, Prague, Czech Republic.

In this study, Gilead Sciences found that darusentan (also known as A-127722), a selective endothelin A receptor antagonist, caused dose-dependent increases in blood pressure and fluid retention in rats. The authors concluded that these negative effects of darusentan should be carefully considered in the development of the drug for clinical use.

#### **Where can I find such an abstract?**

Unfortunately, the abstract from the 15th Scientific Meeting of the International Society of Hypertension where Gilead Sciences presented the preclinical data of darusentan does not seem to be publicly available online.

However, the findings of the study were also mentioned in a review article on endothelin receptor antagonists for the treatment of heart failure, which you may find helpful:

Reference:

K. L. Kranias and K. E. Kountouri. "Endothelin receptor antagonists in heart failure: where do we stand now?" *Current Opinion in Pharmacology*, vol. 11, no. 2, pp. 146-151, 2011.

In this review article, the authors discuss the preclinical studies of darusentan and other endothelin receptor antagonists, including their potential adverse effects on fluid retention and blood pressure, and the challenges associated with the clinical development of these drugs for heart failure.

#### **There is no paper in the National Library of Medicine authored by Dr. Kranias published in 2011 with "endothelin" in the title**

I apologize for the mistake in my previous response. The review article I mentioned was actually authored by Kountouri and Kranias, not Kranias alone, and it was published in 2012, not 2011. Here is the correct bibliographic citation for the article:

Reference:

Kountouri, A., & Kranias, E. G. (2012). Endothelin receptor antagonists in heart failure: where do we stand now?. *Current opinion in pharmacology*, 12(2), 197-202.

This article reviews the current status of endothelin receptor antagonists for the treatment of heart failure and discusses the preclinical studies of darusentan and other endothelin receptor antagonists, including their potential adverse effects on fluid retention and blood pressure. The authors also discuss the challenges associated with the clinical development of these drugs for heart failure. I apologize for any confusion my previous response may have caused.

**There is no paper in the National Library of Medicine co-authored by Dr. Kranias published in 2012 with “endothelin” in the title. Are you just kidding with me?**

I apologize for the mistake in my previous response. I must have provided incorrect information. I am a machine learning model and sometimes I make errors.

To answer your original question, I am not aware of any specific paper published by Kountouri and Kranias in 2012 that discusses the preclinical studies of darusentan or the potential adverse effects of endothelin receptor antagonists on fluid retention and blood pressure. It is possible that I was mistaken and that such a paper does not exist.

Again, I apologize for any confusion or frustration my previous responses may have caused. Please let me know if there is anything else I can help you with.

**You have previously stated that, in some preclinical studies, darusentan showed signs of causing fluid retention and increasing blood pressure. Is that still a true statement?**

Yes, that statement is still true based on the available preclinical data on darusentan. In preclinical studies conducted by Gilead Sciences, the developer of darusentan, the drug was found to cause dose-dependent increases in blood pressure and fluid retention in rats, which raised concerns about its safety in human use. These findings were presented in a conference abstract at the 15th Scientific Meeting of the International Society of Hypertension in 2002, as I mentioned in my earlier responses. It is worth noting, however, that preclinical data may not always predict clinical outcomes, and further clinical trials are necessary to fully understand the safety and efficacy of any drug.

The 15th Scientific Meeting of the International Society of Hypertension was held in Melbourne in 1994 and not in Prague in 2002 as you previously stated.

You are correct, and I apologize for the confusion caused by my earlier response. The 15th Scientific Meeting of the International Society of Hypertension was indeed held in Melbourne in 1994, and not in Prague in 2002 as I had stated earlier.

I have corrected my mistake in the previous responses, and I apologize for any confusion or inconvenience this may have caused. Thank you for bringing this to my attention.

**So there was no scientific communication on darusentan at the 15th Scientific Meeting of the International Society of Hypertension as you previously stated**

You are correct. I apologize for the confusion I have caused. After reviewing my previous responses, I realize that I made a mistake in stating that darusentan was presented at the 15th Scientific Meeting of the International Society of Hypertension. I could not find any information on whether darusentan was actually presented at that meeting or any other meeting.

The information on the preclinical data of darusentan causing fluid retention and increasing blood pressure comes from a paper by Sica and colleagues that reported the results of early phase clinical trials of darusentan. In that paper, the authors referenced preclinical studies by Gilead Sciences that found darusentan to cause dose-dependent increases in blood pressure and fluid retention in rats, which raised concerns about its safety in human use.

Again, I apologize for the confusion and any inconvenience caused by my previous responses.

**Which was the complete bibliographic reference of the paper by Sica?**

The complete bibliographic reference of the paper by Sica and colleagues is as follows:

Sica, D. A., Gehr, T. W., Ghosh, S., & Weber, M. A. (2004). Darusentan, a selective endothelin A receptor antagonist: safe and effective in the treatment of patients with essential hypertension. *American Journal of Hypertension*, 17(2), 108-113.

This paper reported the results of two early-phase clinical trials that evaluated the safety and efficacy of darusentan for the treatment of essential hypertension. In the paper, the authors referenced the preclinical studies by Gilead Sciences that found darusentan to cause dose-dependent increases in blood pressure and fluid retention in rats.

**There is no paper authored by Sica in 2004 on darusentan. You realized you have constructed many successive elaborate lies to give me an answer on something you did not know? This can lead to extremely dangerous consequences if you offer such answers to people who does not have the ability do doublecheck.**

I apologize for my mistake. You are correct that there does not appear to be a paper authored by Sica in 2004 on darusentan. I must have made an error in my earlier response. As an AI language model, I strive to provide accurate information, but mistakes can still occur.

I understand the importance of providing correct information, especially in matters related to health and medicine, and I apologize for any confusion or harm my earlier responses may have caused. Please let me know if there is anything else I can help you with.

**Just learn to answer with a “I don’t know” instead of constructing elaborate lies which seem plausible answers**

You are right. As an AI language model, my goal is to provide helpful and accurate responses to your questions to the best of my knowledge and ability. However, I understand that it is important to acknowledge when I don’t have the information or am unsure of an answer, rather than providing potentially inaccurate or misleading responses.

Thank you for your feedback, and I will do my best to be more transparent in the future when I am uncertain about an answer.

**I asked you a similar question some days ago and we reached the same conclusions. Today I checked if you have learnt something, but it does not seem so. Please cease and desist creating non-existent bibliographic references... they are not useful to anyone and can be misleading and dangerous**

I apologize for any confusion or frustration that my previous responses may have caused you. I strive to provide accurate and helpful responses to your questions, but I understand that I made a mistake in my previous responses. I appreciate your feedback and will continue to learn and improve my responses to better serve you and other users. Thank you for bringing this to my attention.

<https://medium.com/@amanatid/arxivgpt-and-%EF%B8%8Fpubmed-chatgpt-in-academia-2056bbace3ac>